• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Using a Universal GMP Assay for PDE Research

by Bellbrook Labs / Thursday, 28 January 2021 / Published in HTS Assays, Uncategorized
GMP Assay for PDE Inhibitor Discovery

A universal GMP assay to aid in PDE research and potential COVID-19 disruption. – Phosphodiesterase enzymes (PDEs) modulate pathways throughout the body. Since unregulated PDEs contribute to disease in many cases, it makes sense therapies that inhibit these enzymes have the potential to treat several different ailments. These include cardiovascular and respiratory issues, diabetes, fibrotic disorders, and peripheral nerve damage. At the regulation level, the PDE enzymes degrade second messengers such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).¹

These second messengers trigger many cell signaling functions within the human body. Respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma combined affect at least 300 million people worldwide. There is an increasing need for therapeutic agents to treat illnesses that attack the respiratory tract. The obstruction to the airway in COPD is not fully reversible, while it can be in asthma patients. Some COPD patients are given a variety of therapeutic agents combined with roflumilast, a PDE 4 inhibitor to minimize the symptoms.²

Many researchers focus on the ubiquitous cAMP and cGMP second messengers when finding ways to eliminate or decrease symptoms of respiratory diseases. These molecules play essential roles in regulating cellular functions in the lung, including but not limited to the airway smooth muscle (ASM) tone, cell proliferation, differentiation, apoptosis, migration, secretion of inflammatory mediators, deposition of extracellular matrix, and the maintenance of the endothelial and epithelial barrier.  A GMP assay is one such tool to aid in this research.

PDE Inhibitors and COVID-19

Just as there are several subtypes of PDEs, there is an assortment of PDE-specific and non-selective inhibitors currently being used to treat a variety of different illnesses. Even though there are inhibitors already on the market treating disease, there’s room for discovery, especially as new conditions like COVID-19 emerge.

In fact, Giorgi et al. have suggested the use of PDE4 and PDE5 inhibitors to curb COVID-19 symptoms as they have had success in COPD and high altitude pulmonary edema (HAPE) patients – respiratory diseases with similar pathology to COVID-19. PDE5 is found in airways and vascular smooth muscle and has been shown to regulate via the cGMP-PKG signaling pathway. Inhibitors increase cGMP levels with anti-inflammatory effects and reduce pulmonary hypertension, both of which are issues found in COVID-19 patients.²

As PDEs are critical elements within the cGMP cascade, it’s no surprise that many scientists are working to understand the basic science and move closer to drug discoveries. These are breakthroughs that will assist with the current pandemic and have lasting impacts on many diseases, and GMP assay kits can help accelerate this work.

GMP Assay for Measuring PDE Activity

Researchers have already started discovering PDE inhibitors to combat a plethora of illnesses, including respiratory disease; however, there is much to learn and even more potential for drug discovery. The Transcreener® AMP²/GMP² Assay can detect PDE activity through direct detection of GMP (or AMP).  A PDE enzyme converts a precursor cGMP to the product GMP, which displaces a fluorescent tracer from a highly selective antibody. The result is a change in fluorescence, which can be read as an FI, FP, or TR-FRET readout. This robust measurement of PDE activity can be used to discover new inhibitors via HTS and lead discovery campaigns, thus helping many patients suffering from respiratory issues and a range of other illnesses.

References

1. Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019). Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacology and Therapeutics, 197, 225–242. https://doi.org/10.1016/j.pharmthera.2019.02.002

2. Giorgi, M., Cardarelli, S., Ragusa, F., Saliola, M., Biagioni, S., Poiana, G., … Massimi, M. (2020). Phosphodiesterase inhibitors: Could they be beneficial for the treatment of COVID-19? International Journal of Molecular Sciences, 21(15), 1–11. https://doi.org/10.3390/ijms21155338

Tagged under: gmp assay, PDE Inhibitors, Phosphodiesterase Assay, Transcreener AMP/GMP Assay

What you can read next

Cancer Cell T Cell CD39 Activity Assay
Immuno-Oncology Drug Discovery: A CD39 Activity Assay for a Promising Target
Inhibitors of ENPP1 SLAS Discovery
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Pink Stethascope DOT1L Breast Cancer Target 420 X 280
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP